Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway

Cell and Tissue Research
Navid KoleiniElissavet Kardami

Abstract

Doxorubicin (Dox)-induced cardiotoxicity, a limiting factor in the use of Dox to treat cancer, can be mitigated by the mitogenic factor FGF2 in vitro, via a heme oxygenase 1 (HO-1)-dependent pathway. HO-1 upregulation was reported to require protein kinase CK2 activity. We show that a mutant non-mitogenic FGF2 (S117A-FGF2), which does not activate CK2, is cardioprotective against acute cardiac ischemic injury. We now investigate the potential of S117A-FGF2 to protect cardiomyocytes against acute Dox injury and decrease Dox-induced upregulation of oxidized phospholipids. The roles of CK2 and HO-1 in cardiomyocyte protection are also addressed.Rat neonatal cardiomyocyte cultures were used as an established in vitro model of acute Dox toxicity. Pretreatment with S117A-FGF2 protected against Dox-induced: oxidative stress; upregulation of fragmented and non-fragmented oxidized phosphatidylcholine species, measured by LC/MS/MS; and cardiomyocyte injury and cell death measured by LDH release and a live-dead assay. CK2 inhibitors (TBB and Ellagic acid), did not affect protection by S117A-FGF2 but prevented protection by mitogenic FGF2. Furthermore, protection by S117A-FGF2, unlike that of FGF2, was not prevented by HO-1 inhibitors and ...Continue Reading

References

Mar 27, 1995·Annals of the New York Academy of Sciences·E KardamiP A Cattini
Feb 9, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Zhi-Sheng JiangElissavet Kardami
Mar 17, 2004·Cardiovascular Research·Zhi-Sheng JiangElissavet Kardami
Sep 11, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Derek J HausenloyDerek M Yellon
May 23, 2007·Heart Failure Reviews·Elissavet KardamiPeter A Cattini
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Apr 24, 2009·Cellular and Molecular Life Sciences : CMLS·J H TrembleyK Ahmed
Aug 11, 2010·Cardiovascular Research·Jon-Jon SantiagoElissavet Kardami
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Feb 23, 2012·Angiogenesis·Dilu FengMatthias W Laschke
Jun 26, 2013·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Christopher W WhiteDarren H Freed
Dec 3, 2014·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Christopher W WhiteDarren H Freed
Mar 17, 2015·Wiley Interdisciplinary Reviews. Developmental Biology·David M Ornitz, Nobuyuki Itoh
Jun 2, 2016·International Journal of Molecular Medicine·Masaru Katoh
Jun 28, 2016·Archives of Toxicology·Roberto Marques DamianiJenifer Saffi
Apr 27, 2017·Oncotarget·Navid Koleini, Elissavet Kardami
Aug 2, 2017·European Journal of Medicinal Chemistry·Loredana SalernoValeria Pittalà
Nov 18, 2017·JACC. Basic to Translational Science·Michael TorzewskiSotirios Tsimikas

❮ Previous
Next ❯

Citations

Dec 16, 2020·International Journal of Molecular Sciences·Márton Richárd SzabóCsaba Csonka
Apr 16, 2021·Oxidative Medicine and Cellular Longevity·Yu JiangLili Yuan

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
Assay

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.